FIG. 7.
Breadth and potency of V3-specific NAbs in plasma of clade B- and clade C-infected subjects. Eleven clade B plasmas (blue) and 10 clade C plasmas (red) were tested for V3-specific neutralizing activity against HIV-2KR.X7 YU2 V3, HIV-2KR.X7 Ccon V3, and HIV-1YU2 (A) and HIV-2KR.X7 BORI V3 and HIV-1BORI (B). Reciprocal IC50s and median values (horizontal lines) are plotted for each plasma-virus combination. IC50s for all plasmas tested against control HIV-2 viruses were all <1:20. Comparisons showing statistical significance are indicated.